GENE ONLINE|News &
Opinion
Blog

2018-10-11| Asia-PacificPolicy

Live Report – 2018 BioJapan: Witness Japan’s biotechnology industry development policy and the innovation of pharmaceutical industry

by GeneOnline
Share To

2018 BioJapan was launched on October 10th at Pacifico Yokohama National Convention Hall. GeneOnline listed some of the highlights shared by two key opinion leaders in medicine.

Concentrate on the development of biotechnology in order to solve the issues on society.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI), mentioned that Japanese government has outlined “Society 5.0” project in “Japan Revitalization Strategy”, in order to integrate the relevant units and implement the effective resource allocation and structural reform.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)
Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)

Regarding to this, Japanese government’s appeal is to let the policy and technology development become closer, more organized and flexible, and commit to expanding the market and accelerating the development of computer science and biotechnology.

The technology integration is real data and domain technology for biotechnology, which combines big data in various fields with cutting edge technologies such as genetic technology, AIoT, bioinformatics, etc. As well as connects to the country that has sound system on biomedical, such as the United States, United Kingdom, Germany, etc., in order to become the well-known country in global biotechnology industry.

The future of drug development and innovation

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA), introduced that JPMA consists of 71 research-based pharmaceuticals in Japan and is a research-oriented voluntary organization.

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)
George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)

He mentioned that Japan should work hard in three directions to catch up with the United States. To begin with, the establishment of the infrastructure, including the establishment of a health care database, such as genome and clinical diagnostic information, and the construction of ID facilities. Then, in order to provide sufficient funds for basic scientific research, the government and industry should cooperate to create profits. Finally, the government should establish an ecosystem without borders, especially establish a close relationship with the United States actively.

“Stay tuned to GeneOnline for more special articles on BioJapan 2018”

medtex最新-e1538653867506

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
R&D
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
LATEST
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top